WAYNE, PA – Egalet Corporation, the Wayne pharmaceutical firm working to bring abuse-deterrent pain medications to market, has appointed Dr. Jeffrey M. Dayno chief medical officer.

Dr. Dayno will be responsible for leading Egalet’s clinical development programs, and will oversee regulatory and medical affairs and pharmacovigilance.

“We would like to welcome Jeff to our management team at this critical time as we move our lead abuse-deterrent product candidate, Egalet-001, through the final phase of development and plan to file an NDA in the fourth quarter,” said Bob Radie, president and CEO.  “Jeff’s deep global pharmaceutical and medical affairs experience in the neurology and pain areas will be invaluable as we advance our product candidates, develop our medical affairs/education strategies and evolve our commercial organization.”

Radie also thanked Dr. Roland Gerritsen van der Hoop, acting CMO, for his guidance over the past few years. He is transitioning to an advisory role at Egalet.

Dr. Dayno spent 10 years in clinical and academic medicine before moving into the pharmaceutical industry.  He most recently served as vice president, global medical affairs, at ViroPharma, a pharmaceutical company which was bought by Shire in 2014. He was a member of several senior R&D leadership teams.

A former practicing neurologist, Dr. Dayno has clinical experience caring for chronic pain patients.  Dr. Dayno has held a number of clinical appointments, including clinical assistant professor of neurology, Jefferson Medical College and medical director of the Jefferson Health Systems Stroke Center Network. He has served as principal investigator on numerous clinical trials, has published and lectured extensively on various topics in the field of neurology, and has been a peer reviewer for several scientific journals.

“Given the need for abuse deterrent pain medications and the potential seen with Egalet’s lead abuse-deterrent product candidates, I am thrilled to be a part of the Egalet team.” said Dr. Dayno. “I look forward to working with the team to achieve the company’s mission of helping to ensure access to effective medications for individuals living with chronic pain while protecting physicians, families and communities.”

Dr. Dayno is also currently a member of the Board of Visitors of Temple University School of Medicine and was a former chairman of the Philadelphia Stroke Council.

Top photo credit: NikonGirl1969 via photopin cc
_________

Follow us on Twitter

Like us on Facebook